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Abstract.
Background: Improved prediction of Parkinson’s disease (PD) progression is needed to support clinical decision-making
and to accelerate research trials.
Objectives: To examine whether baseline measures and their 1-year change predict longer-term progression in early PD.
Methods: Parkinson’s Progression Markers Initiative study data were used. Participants had disease duration ≤2 years,
abnormal dopamine transporter (DAT) imaging, and were untreated with PD medications. Baseline and 1-year change in
clinical, cerebrospinal fluid (CSF), and imaging measures were evaluated as candidate predictors of longer-term (up to 5
years) change in Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) score and DAT
specific binding ratios (SBR) using linear mixed-effects models.
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Results: Among 413 PD participants, median follow-up was 5 years. Change in MDS-UPDRS from year-2 to last follow-up
was associated with disease duration (= 0.351; 95%CI = 0.146, 0.555), male gender (= 3.090; 95%CI = 0.310, 5.869),
and baseline (= –0.199; 95%CI = –0.315, –0.082) and 1-year change (= 0.540; 95%CI = 0.423, 0.658) in MDS-UPDRS;
predictors in the model accounted for 17.6% of the variance in outcome. Predictors of percent change in mean SBR from year-2
to last follow-up included baseline rapid eye movement sleep behavior disorder score (= –0.6229; 95%CI = –1.2910, 0.0452),
baseline (= 7.232; 95%CI = 2.268, 12.195) and 1-year change (= 45.918; 95%CI = 35.994,55.843) in mean striatum SBR,
and 1-year change in autonomic symptom score (= –0.325;95%CI = –0.695, 0.045); predictors in the model accounted for
44.1% of the variance.
Conclusions: Baseline clinical, CSF, and imaging measures in early PD predicted change in MDS-UPDRS and dopamine-
transporter binding, but the predictive value of the models was low. Adding the short-term change of possible predictors
improved the predictive value, especially for modeling change in dopamine-transporter binding.
Keywords: Parkinson’s disease, biomarkers, disease progression, surrogate endpoint
INTRODUCTION
Understanding the progression of Parkinson’s dis-
ease (PD) is crucial to improve clinical management
and to enhance therapeutic research. Offering patients
accurate prognostic information at the time of diag-
nosis would inform patient decision making and
physician management. Accurate baseline or early
disease measures of longer-term outcomes in PD
could improve trial efficiency by optimizing accuracy
of sample size estimates, reducing required trial dura-
tion, and, when desired, informing selection criteria
to allow for enrichment of the sample with partici-
pants who are at known risk of a given outcome.
An increasing array of possible predictors of PD
progression can be explored. Several clinical predic-
tors of motor progression in PD have been identified
and replicated with high level of evidence, includ-
ing age of onset [1] and greater degree of postural
instability and gait disorder (PIGD) manifestations
[1]. Other measures of motor and neuropsychiatric
manifestations may be predictive of motor progres-
sion as well [1–3]. However, clinical measures of
PD are subjective and fluctuate especially early-on
in the disease course [4]. Thus, more objective mea-
sures of PD progression are needed, and multimodal
models that incorporate both clinical measures and
objective biomarkers are being pursued. The Parkin-
son Progression Markers Initiative (PPMI) study was
established with the aim of identifying biomarkers
of PD progression. PPMI is a multi-center longitudi-
nal observational study of PD participants that were
newly diagnosed and untreated at baseline, and a non-
PD comparator group, as previously described [5].
Many groups have applied machine-learning tech-
niques to PPMI data to explore multimodal models
for PD diagnosis, subtyping, and modeling of pro-
gression [6–8]. While yielding interesting insights
and promising results, replication and reproducibility
of the models remain to be demonstrated. In addition,
machine learning techniques have not yet provided
clinically relevant predictive models, despite the inte-
gration of massive amounts of multimodal data. For
example, in one study, machine learning was applied
to 17,499 data points derived from clinical, genetic,
imaging, and biofluid biomarker data from PPMI [7].
The best model accounted for 27% of the variation
in motor progression, as measured by the Movement
Disorders Society Unified Parkinson’s Disease Rat-
ing Scale (MDS-UPDRS), a validated rating scale
comprised of patient- and physician-assessed symp-
toms and examination findings. Thus, models that
account for a greater proportion of the variance in out-
come are needed. Much of the literature on predicting
PD progression has focused on single measures at
a baseline timepoint in longitudinal studies. Given
the variability of PD across and within subjects, even
early on in the disease, it would be of value to examine
whether the short-term change of possible predictors
improves the predictive utility of models of progres-
sion over the longer-term.
While many tools now exist to measure and define
PD progression, change in MDS-UPDRS (or its
predecessor UPDRS) remains the most commonly
used clinical trial outcome. Among current potential
objective measures of disease progression, dopamine
transporter (DAT) ligand binding has emerged as a
key outcome of interest. DAT binding and MDS-
UPDRS motor scores have significant but weak
correlation longitudinally [9], and they likely mea-
sure different processes and effects on functional
outcome. The objectives of this analysis were to
examine baseline predictors of change in total and
motor MDS-UPDRS and DAT imaging over the first
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5 years of PD diagnosis, and to assess the utility
of adding the 1-year change of predictors into the
predictive models.
METHODS
Sample
PPMI is a multicenter international prospective
cohort study. Study aims and methodology have
been published elsewhere [5] and are available on
the PPMI website (http://www.ppmi-info.org/study-
design). Briefly, PD participant enrollment criteria
included (i) presence of 2 or more of the follow-
ing: bradykinesia, rigidity, and resting tremor OR
presence of either an asymmetric resting tremor or
asymmetric bradykinesia (ii) disease duration from
diagnosis of ≤2 years, (iii) dopamine transporter
deficit on SPECT imaging. Participants could not be
treated for PD or expected to need treatment within 6
months of enrollment. A comparator group of gener-
ally healthy individuals without PD (healthy controls,
HC) were also enrolled. Enrollment criteria for the
HC group were: (i) no significant neurologic dys-
function (ii) no 1st-degree relative with PD (iii) and a
Montreal Cognitive Assessment (MOCA) score >26.
At enrollment both PD and HC groups could not have
contraindications to lumbar puncture or a diagnosis
of dementia as determined by the investigator.
Only PD and HC participants with at least 1 post-
baseline assessment for at least one outcome were
included in this analysis. Data downloaded from
www.ppmi-info.org/data on November 6, 2017 were
used for this analysis.
Assessments
The following assessments were administered:
– Demographics: age at baseline, gender, educa-
tion
– Body mass index: weight/height2 (kg/m2)
– Motor severity: Movement Disorders Soci-
ety Unified Parkinson’s Disease Rating Scale
(MDS-UPDRS) [10] scores from the baseline
and annual assessments during years 1–5 were
considered for this analysis. A tremor score
and postural instability gait disorder (PIGD)
score were generated (see Supplementary Meth-
ods) [11]. Once participants started levodopa
and/or dopamine agonists (dopaminergic ther-
apy, DT), the MDS-UPDRS total/part III in
the relative OFF and ON medication states
were considered separately. The “relative OFF”
MDS-UPDRS part III score was obtained after
subjects withheld levodopa or dopamine ago-
nist for at least 6 hours. Other PD medications
were not held for OFF testing. Previously pub-
lished work has demonstrated that the duration
of OFF did not appreciably influence the change
in MDS-UPDRS score over time [9]; also see
the Supplementary Materials). The ON MDS-
UPDRS part III score was obtained 1 hour
after administration of prescribed medications.
For a given visit, when OFF testing was not
obtained, the MDS-UPDRS OFF score was
considered missing and only ON scores were
considered.
– Functional abilities: Modified Schwab and Eng-
land Activities of Daily Living Scale (S&E) was
administered at baseline in PD and HC groups
and annually in the PD group.
– Cognition: Montreal Cognitive Assessment
[12]. Baseline and annual assessments during
years 1–5 in the PD and HC were considered
for this analysis.
– Psychiatric symptoms: 15-item Geriatric
Depression Scale [13] and State and Trait
Anxiety Scale [14] were administered. Baseline
and annual assessments during years 1–5 were
considered for this analysis.
– Autonomic: Scales for Outcomes in PD-
Autonomic (SCOPA-AUT) [15] was admin-
istered. Blood pressure and heart rate were
measured in supine position and standing posi-
tion. Baseline and annual assessments during
years 1–5 were considered for this analysis.
– Sleep/Sleepiness: Epworth Sleepiness Scale
(ESS) and REM Sleep Behavior Disorder Ques-
tionnaire (RBDSQ) were administered. Baseline
and annual assessments during years 1–5 were
considered for this analysis.
– Imaging: DAT SPECT scan was performed
using the radionuclide ligand DatScan™ as pre-
viously described [5] at baseline in the PD and
HC group and subsequently at years 1, 2, and
4 only in the PD group. Mean striatal specific
binding ratio (SBR; average of putamen and cau-
date SBR on right and left) and mean putamen
SBR were the DAT measures of interest in this
analysis.
– PD therapy: PD medication intake was captured
in logs. Time to PD medication was ascer-
tained as previously described [16]. Levodopa
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equivalent daily dose (LEDD) were calculated
as previously described [17].
– Biofluid biomarkers: cerebrospinal fluid (CSF)
was collected via lumbar puncture at baseline,
6 months, annually thereafter. -amyloid 1–42
[A1–42], total tau [T-tau], tau phosphorylated
at threonine 181 [P-tau181], and unphosphory-
lated -synuclein [-Syn]) were measured as
previously described [18].
Analysis
Outcome measures of progression
Three main outcome measures of progression were
selected for examination:
(1) Absolute change in total MDS-UPDRS score
(sum of parts I–III)
(2) Absolute change in the MDS-UPDRS part III
motor subscore and
(3) Percent change from baseline in DAT measures
(mean striatal SBR and mean putamen SBR).
Once participants began DT, the MDS-UPDRS
part III score was measured in the ON and OFF state,
as defined above, and OFF and ON total and part III
subscores were considered as outcome measures in
separate statistical models (see below).
Selection of predictors
The primary objective of this analysis was to
identify variables for which the baseline and 1-year
change predict longer-term change in PD. All putative
clinical, imaging, and biofluid measures collected in
PPMI that could be baseline predictors of change and
had the possibility to change over time were included
(thus, we did not examine genetic predictors). The
exceptions were age, gender, and disease duration
at baseline, all of which were included in all mod-
els to mitigate any potential confounding between
identified predictors and the outcome.
Variables were selected as candidate short-term
change predictors (STP) if they met the following
criteria:
(i) Significant difference in change from baseline
to 1 year in the PD group vs. the HC group
(for variables measured in both groups at these
time points; this step was necessary in order to
focus on STP specific to PD and not those that
change in the course of “normal aging”) and
(ii) Significant change in the PD group from base-
line to 1 year
An exception to these criteria was made for
S&E and DATscan SPECT since these were only
performed longitudinally in the PD group. These
measures were selected as STP if they changed sig-
nificantly in the PD group over 1 year.
For selection of the STP, significant change was
defined statistically as p < 0.05, using two-sample t-
test, Wilcoxon signed rank sum, or McNemar’s test
as appropriate.
Model building
As mentioned, data were limited to PD subjects
with at least 1 annual follow-up (n = 413). Baseline
characteristics were summarized using descriptive
statistics. The analysis was conducted in 4 steps.
Step 1: Each outcome was modeled from base-
line to last follow-up (up to year 5) with linear and
non-linear time models and a variety of covariance
structures (see Supplementary Material; Supple-
mentary Table 1). The optimal model fit for the
MDS-UPDRS and mean striatum outcomes was a
linear time model with a random intercept and slope
and an unstructured covariance structure. The optimal
model for mean putamen was a linear time model with
a random intercept and an unstructured covariance
structure.
Step 2: Next, associations between the outcomes
and baseline predictors were examined by fitting
pseudo-univariate models including the predictors of
interest with a model adjusted for the baseline value of
the respective outcome. The term pseudo-univariate
(as opposed to univariate) is used to denote that base-
line age, gender, and baseline disease duration were
forced into the backwards selection model along with
the baseline outcome value (regardless of their p-
value). All baseline predictors that had a p-value
<0.20 were next included in a multivariate model. The
multivariate linear mixed-effects model was reduced
to a final model using backwards selection where
predictors with p-values >0.10 were eliminated.
Step 3: After the best-fit models were constructed
with the baseline predictors, we next incorporated the
STP variables. To examine whether the STP add any
additional predictive ability to the model, above that
of only baseline predictors, we adjusted all STP mod-
els for the significant baseline predictors identified in
step 2, along with baseline age, gender, baseline dis-
ease duration, and the baseline outcome value. For
the models examining STP, change in the key out-
comes was measured from year-2 to last follow-up
(up to year 5). Thereby, associations between the key
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outcomes (starting at year 2 to last follow-up) and
STP were tested. All STP with a p-value <0.20 were
included in a multivariate model. Backwards selec-
tion was performed on the multivariate model using
a 0.10 significance level.
Step 4: In order to compare the amount of varia-
tion explained by the addition of the STP, a method
by Seyla et al. [19] was used to compute a coefficient
of variation, R2, for each of the final multivariate
models. The R2 was calculated by computing the
proportion of the variance accounted for by the pre-
dictors:
R2 = Vnull − Vfull
Vnull
, (1)
where Vnull is the residual variance of a model with
only random effects and Vfull is the residual vari-
ance of a model with predictors and random effects.
To ensure the reduction in variance was only due to
the predictors, the variance explained by the random
effects was held constant at that of the final STP mod-
els. For comparison, it was also necessary to model
the outcomes over the same time points and with
equal sample sizes to the final STP models.
To evaluate the replication stability of selected pre-
dictors in our models we performed cross-validation.
The data were randomly split in to two folds with-
out replacement to form a training and a test data set.
The training data set was fit with pseudo-univariate
models and backwards selection was performed with
the test data set. The same model building was per-
formed in each step as described above. The number
and percent of times the predictor was in the final
backwards selection model was reported out of 1000
iterations [20, 21]. Higher selection percentage (SP)
indicates more validity of the predictor. The fold
assignment was varied at each iteration so that the
pseudo-univariate and multivariate models were fit
on a different subset of the data each iteration. Within
each iteration, the same grouping was used when fit-
ting each pseudo-univariate model for the various
predictors. Selection frequencies are not reported for
variables forced into the multivariate models since
they are not considered in the backwards selection
algorithm.
RESULTS
413 PD and 185 HC participants were included in
this analysis (Table 1). Mean age was 61.69 (SD 9.77)
years and 61.01 (SD 11.16) in the PD and HC groups
respectively. 339 (82.08%) were enrolled at US sites
and 74 (17.92%) at non-US. Other baseline and year
1 characteristics of this cohort are shown in Table 1.
Summary statistics for each of the outcome measures
are shown in Table 2.
Median follow up time for the PD group was 60
months. 375 participants (91%) of the sample had at
least 3 years of follow-up.
Pseudo-univariate relationships between each
baseline predictor and the outcome measures are
shown in Supplementary Table 2, as are the relation-
ships for these variables with the outcome measures
examined in the final models (after backwards selec-
tion was applied as per step 2 of the model building,
as described above). The selection frequencies from
the cross-validation are also shown in Supplementary
Table 2.
Multivariate models of baseline predictors of
long-term change in MDS-UPRDS
Table 3 (Supplementary Table 2) shows signifi-
cant (p≤ 0.10) baseline predictors of change from
baseline of total MDS-UPRDS score in the OFF
state. These were baseline disease duration, MDS-
UPDRS total score in the OFF state, male gender,
CSF amyloid-1–42 (SP = 28.6%), mean striatum
SBR (SP = 16.1%), orthostatic SBP (SP = 0.1%), and
SCOPA-AUT (SP = 1.2%).
Baseline MDS-UPDRS total score in the ON
state, male gender, CSF amyloid-1–42 (SP = 7.5%),
MoCA score (SP = 1.4%), and SCOPA-AUT score
(SP = 0.70%) were significant predictors for the
model examining total MDS-UPRDS score in the ON
state.
When the change from baseline in the part III sub-
score of MDS-UPRDS in the OFF state was examined
as the outcome, significant predictors were base-
line disease duration, baseline MDS-UPDRS part III
subscore in the OFF state, US site (SP = 25.4%), base-
line CSF amyloid-1–42 (SP = 10.9%), and baseline
mean striatum SBR (SP = 7.2%).
When the change from baseline in the ON state part
III subscore was the outcome, baseline disease dura-
tion, baseline MDS-UPDRS part III subscore in the
ON state CSF amyloid-1–42 (SP = 0.8%), and US
site (SP = 20.9%) continued to be significant. Base-
line mean striatum SBR was no longer significant
and baseline Epworth sleepiness scale score became
significant (SP = 0.5%) (in comparison to the model
for which the OFF state part III subscore was the
outcome).
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Table 1
Baseline and 1-year values of clinical, biofluid biomarker, and imaging variables in the PD group and HC groups. NC, not collected as per study protocol; BMI, body mass index; CSF, cerebrospinal
fluid; ESS, Epworth Sleepiness Scale; GDS-15, 15-item Geriatric Depression Scale; PIGD, postural instability gait disorder; MoCA, Montreal Cognitive Assessment; RBDSQ, REM Sleep Behavior
Disorder Questionnaire; SBR, specific binding ratio; SCOPA-AUT, Scales for Outcomes in Parkinsons—Autonomic; SBP, systolic blood pressure
Variable PD group HC group p-value for significance
(N = 413) (N = 185) of difference:
BL∗ 1 year∗ BL∗ 1 year∗ from BL to from BL to
1 year, PD 1 year in
vs HC PD group
H&Y score (N) H&Y 0:0 H&Y 0:1 H&Y 0:182 H&Y 0:178 n/a∗∗ <0.0001∗∗
H&Y 1:181 H&Y 1:99 H&Y 1:2 H&Y 1:3
H&Y ≥2:232 H&Y ≥2:233 H&Y ≥2:0 H&Y ≥2:4
Missing: 0 Missing: 80 Missing: 1 Missing: 0
BMI (kg/m2) 27.1 (4.6; 16.9–43.8; 3) 26.8 (4.6; 16.7–44.2; 40) 26.9 (4.4; 17.5–42.3; 1) 27.18 (4.9; 18.0–45.4; 1) 0.0002 0.0003
Schwab and
England total
score (S&E)
93.2 (5.9; 70–100; 0) 90.5 (6.7; 70–100; 20) NC NC NC <0.0001
Tremor score 0.5 (0.3; 0–1.8; 19) 0.6 (0.4; 0–2;79) 0.0 (0.1; 0–0.6; 1) 0.1 (0.1; 0–0.6; 1) 0.0006 <0.0001
PIGD score 0.2 (0.2; 0–14; 1) 0.3 (0.3; 0–1.8; 79) 0.0 (0.1; 0–0.8; 1) 0.0 (0.1; 0–0.6; 1) 0.0001 <0.0001
GDS-15 Total
Score
2.3 (2.4; 0–14; 0) 2.6 (2.9; 0–15; 18) 1.3 (2.1; 0–15; 0) 1.4 (2.4; 0–15; 0) 0.6046 0.0828
SCOPA-AUT
Total Score
9.4 (6.2; 0–39; 8) 10.9 (6.4; 0–45, 23) 5.8 (3.7; 0–20; 2) 5.8 (4.4; 0–22; 2) 0.0001 <0.0001
STAI Score 65.2 (18.2; 40–137; 1) 65.2 (18.7; 40–142; 18) 57.0 (14.1; 40–105; 0) 56.2 (16.7; 40–128; 0) 0.5840 0.7460
ESS total score 5.7 (3.4; 0–20; 0) 6.1 (4.0; 0–21; 18) 5.6 (3.4; 0–19; 1) 5.4 (3.2; 0–16; 1) 0.0409 0.0240
RBDSQ total
score
4.1 (2.7; 0–12; 3) 4.1 (2.8; 0–13; 20) 2.8 (2.2; 0–11; 0) 2.8 (2.3; 0–11; 0) 0.9704 0.9154
Orthostatic SBP
change
4.7 (12.7; –31–72; 1) 3.9 (13.1; –32–58; 20) 1.9 (12.3; –47–41; 0) 1.6 (10.5; –26–30; 0) 0.6911 0.1679
Mean striatum
SBR
1.41 (0.39; 0.31–2.64; 3) 1.24 (0.4; 0.2–2.7; 45) 2.6 (0.6; 0.98–4.2; 1) NC NC <0.0001
Mean putamen
SBR SBR
0.8 (0.3; 0.2–2.1; 3) 0.7 (0.3; 0.05–2.3; 45) 2.14 (0.5; 0.6–3.9; 1) NC NC <0.0001
MoCA 27.1 (2.3; 17–30; 3) 26.3 (2.8; 15–30; 21) 28.2 (1.1; 26–30; 0) 27.3 (2.2; 20–30; 0) 0.5736 <0.0001
CSF
amyloid-1–42
849.10 (320.8; 238.8–1664.0; 68) 818.20 (310.3; 249.5–1645.0; 116) 899.54 (333.2; 239.1–1632.0; 36) 930.9 (318.9; 312–1611; 52) 0.0080 0.1194
CSF Total-Tau 168.9 (57.0; 80.9–467.0; 55) 169.1 (58.4; 82.2–388.7; 99) 192.3 (79.2; 82.0–580.8; 23) 200.4 (83.1; 82.4–600.1; 37) 0.0851 0.8698
CSF Phoso-Tau181 14.9 (5.2; 8.0–40.1; 82) 14.9 (5.3; 8.2–34.3; 127) 17.6 (8.5; 8.2–73.6; 32) 18.2 (9.0; 8.3–80.1; 44) 0.0336 0.7021
CSF -Synuclein 1494.3 (672.1; 432.4– 5256.9; 45) 1425.5 (619.3; 420.0–3685.3; 88) 1709.3 (761.2; 488.6–4683.1; 19) 1778.9 (788.4; 517.1–4388.6; 32) 0.0016 0.0032
∗Values shown are mean (SD; range (min–max); number missing) for all continuous variables. ∗∗Hoehn and Yahr was the only variable examined as a categorical variable. The count in each stage
followed by the number missing is indicated (H&Y 0:1:≥2; missing). Change is defined as change from 1 or 2 to >2. Comparison between the PD and HC group was not possible due to the small
number of HC participants with H&Y >0 at any time points.
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In all models examining change from baseline in
the MDS-UPDRS and its part III subscore as an
outcome the proportion of variance in the outcome
accounted for by the predictors in the model did not
exceed 15% for the OFF scores, and for the ON state
scores was <5%.
Multivariate models of baseline predictors of
long-term change in DaTscan binding measures
When percent change from baseline in mean puta-
men SBR was examined as the outcome, baseline
CSF amyloid-1–42 (SP = 12.70%), mean putamen
score (SP = 97.80%) and RBDSQ (SP = 56.00%)
were the only predictors (Table 3; Supplementary
Table 2). In contrast, when percent change from base-
line in mean striatal SBR was the outcome, both
baseline RBDSQ (SP = 85.30%) and baseline S&E
(SP = 9.50%) were significant clinical predictors, as
were baseline CSF amyloid-1–42 (SP = 9.80%) and
baseline mean striatum SBR (SP = 65.40%). 29% and
36% of the variance in change in putamen and striatal
DAT binding respectively was accounted for by these
baseline predictors.
Short-term changes in candidate predictors
Table 1 shows the change from baseline to year-1
in all considered variables. Candidate STP that met
criteria for consideration in the multivariate mod-
els were: BMI, S&E, tremor score, PIGD score,
SCOPA-AUT Total Score, ESS, CSF -synuclein,
mean striatal SBR, and mean putamen SBR.
Univariate relationships between STP and the out-
come measures are shown in Supplementary Table 3
(1-year-changes (1-yr-)), as are the relationships for
these variables with the outcome measures in the final
models (after backwards selection was applied as per
step 3 of the model building, as described above).
The selection frequencies from the cross-validation
are also shown in Supplementary Table 3.
Multivariate models of short-term change
predictors of longer-term change in
MDS-UPRDS
Table 4 (Supplementary Table 3) shows results
of the multivariate mixed models examining predic-
tors of change in key outcomes (from year 1 to last
annual follow-up), but including the 1-yr- of the
STPs, as well as the baseline variables significantly
associated with the key outcomes. Importantly, after
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Table 3
Final results of mixed models examining baseline predictors of outcomes. Only variables associated with the outcome at a p-value of ≤0.10 are
listed here. For the full model, see Supplementary Table 2. BMI, body mass index; CSF, cerebrospinal fluid; ESS, Epworth Sleepiness Scale;
PIGD, postural instability gait disorder; MoCA, Montreal Cognitive Assessment; RBDSQ, REM Sleep Behavior Disorder Questionnaire;
SBR, specific binding ratio; SCOPA-AUT, Scales for Outcomes in Parkinsons—Autonomic; SBP, systolic blood pressure
Outcome Predictor (All baseline values)i Multivariate Effect Estimate Multivariate Multivariate
 (95% CI) p-value Adjusted R2
MDS-UPDRS Total Score
OFF - Change from Baseline
Disease duration 0.1596 (0.0204, 0.2988) 0.0246
MDS-UPDRS total score in OFF –0.1345 (–0.2097, –0.0593) 0.0005 0.1383
N = 373 Gender (Male) 1.9042 (0.0550, 3.7535) 0.0436
CSF amyloid-1–42 –0.0031 (–0.0058, –0.0005) 0.0217
Mean striatum SBR –2.5317 (–4.8456, –0.2179) 0.0320
SBP –0.0779 (–0.1468, –0.0090) 0.0267
SCOPA-AUT 0.1413 (–0.0174, 0.3000) 0.0809
MDS-UPDRS Total Score
ON - Change from Baseline
MDS-UPDRS total score in ON –0.1990 (–0.2721, –0.1260) <0.0001
CSF amyloid-1–42 –0.0028 (–0.0054, –0.0001) 0.0407 0.0533
N = 374 Gender (Male) 1.6797 (–0.1650, 3.5244) 0.0743
MoCA –0.3482 (–0.7439, 0.0474) 0.0844
SCOPA-AUT 0.1487 (–0.0105, 0.3079) 0.0671
MDS-UPDRS Part III Score
OFF - Change from Baseline
Disease duration 0.1377 (0.0405, 0.2349) 0.0055
MDS-UPDRS part III score OFF –0.1849 (–0.2567, –0.1131) <0.0001 0.1156
N = 382 Clinical Site (US) 1.1952 (0.2462, 3.5841) 0.0246
CSF amyloid-1–42 –0.0021 (–0.0039, –0.0002) 0.0284
Mean striatum SBR –1.6005 (–3.1793, –0.0218) 0.0469
MDS-UPDRS Part III Score
ON - Change from Baseline
Disease duration 0.1239 (0.0252, 0.2227) 0.0140
MDS-UPDRS part III score ON –0.2497 (–0.3199, –0.1795) <0.0001 0.0345
N = 385 Clinical Site (US) 1.9541 (0.3446, 3.5636) 0.0174
ESS –0.1572 (–0.3351, 0.0207) 0.0833
CSF amyloid-1–42 –0.0019 (–0.0038, –0.0001) 0.0417
Mean putamen SBR -
% Change from Baseline
CSF amyloid-1–42 0.0055 (–0.0001, 0.0111) 0.0526 0.2870
Mean putamen SBR –17.1848 (–23.6240, –10.7457) <0.0001
N = 352 RBDSQ –1.0837 (–1.7730, –0.3945) 0.0021
Mean striatum SBR -
% Change from Baseline
CSF amyloid-1–42 0.0039 (–0.0003, 0.0081) 0.0708
Mean striatum SBR –6.2020 (–9.7532, –2.6508) 0.0007 0.3563
N = 351 Modified Schwab & England (S&E) 0.2417 (0.0037, 0.4797) 0.0466
RBDSQ –1.0030 (–1.5268, –0.4793) 0.0002
iAge, gender, disease duration, and the baseline value of the outcome were forced into each model.
adjustment for the short-term change in total MDS-
UPDRS OFF score, many of the significant baseline
predictors noted above (CSF amyloid-1–42, mean
striatum, baseline SBP, baseline SCOPA) become
non-significant. In the final model, change from base-
line in total MDS-UPDRS score in the OFF state was
significantly associated with baseline disease dura-
tion, male gender, baseline MDS-UPDRS score in the
OFF state, and 1-yr- in total MDS-UPDRS score in
the OFF state (SP = 99.90%).
For the model examining change from baseline in
total MDS-UPDRS score in the ON state as the out-
come, significant predictors included baseline disease
duration, baseline total MDS-UPDRS score in ON
state, baseline SCOPA-AUT, baseline CSF amyloid-
1–42, male gender, 1-yr- in total MDS-UPDRS
score in the ON state (SP = 99.90%), and 1-yr- in
SCOPA-AUT (SP = 34.40%). Compared to the model
only containing the baseline predictors, MoCA was
not a significant predictor.
When the long-term change from baseline in the
part III subscore of the MDS-UPDRS in the OFF
state was the outcome, baseline disease duration,
male gender, baseline part III subscore of the MDS-
UPDRS in the OFF state, 1-yr- in part III subscore
of the MDS-UPDRS (SP = 100.00%), 1-yr- in BMI
(SP = 2.10%), and 1-yr- PIGD score (SP = 20.60%)
were significant predictors.
Predictors of long-term change in part III sub-
score of the MDS-UPDRS in the ON state, on the
other hand, included US site, male gender, base-
line CSF amyloid-1–42, baseline part III subscore
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Table 4
Final results of mixed models examining baseline and short-term change predictors of outcomes. Only variables associated with the outcome
at a p-value of ≤0.10 are listed here. For the full model, see Supplementary Table 3. BMI, body mass index; CSF, cerebrospinal fluid; ESS,
Epworth Sleepiness Scale; PIGD, postural instability gait disorder; RBDSQ, REM Sleep Behavior Disorder Questionnaire; SBR, specific
binding ratio; SCOPA-AUT, Scales for Outcomes in Parkinsons—Autonomic; SBP, systolic blood pressure
Outcome Predictori Multivariate Effect Estimate Multivariate Multivariate
 (95% CI) p-value Adjusted R2
MDS-UPDRS Total Score
Off - Change from
Baseline
Baseline disease duration 0.3506 (0.1457, 0.5554) 0.0009
Baseline MDS-UPDRS Total Score Off –0.1986 (–0.3149, –0.0822) 0.0009 0.1763
1-yr- MDS-UPDRS Total Score Off 0.5403 (0.4228, 0.6578) <0.0001
N = 280 Gender (Male) 3.0895 (0.3104, 5.8687) 0.0295
MDS-UPDRS Total Score
On - Change from
Baseline
Baseline disease duration 0.2087 (0.0075, 0.4098) 0.0421
Baseline CSF amyloid-1–42 –0.0039 (–0.0077, –0.0002) 0.0414 0.0943
Gender (Male) 4.0093 (1.3736, 6.6451) 0.0030
N = 329 Baseline MDS-UPDRS Total Score On –0.2384 (–0.3492, –0.1276) <0.0001
Baseline SCOPA-AUT 0.3266 (0.0766, 0.5767) 0.0106
1-yr- MDS-UPDRS Total Score On 0.4985 (0.3953, 0.6018) <0.0001
1-yr- SCOPA-AUT 0.3629 (0.0623, 0.6636) 0.0181
MDS-UPDRS Part III
Score Off - Change
from Baseline
Baseline disease duration 0.1558 (0.0152, 0.2965) 0.0301
Gender (Male) 1.7635 (–0.1740, 3.7009) 0.0743 0.1719
Baseline MDS-UPDRS Part III Score Off –0.1690 (–0.2823, –0.0557) 0.0036
N = 264 1-yr- MDS-UPDRS Part III Score Off 0.5155 (0.3875, 0.6436) <0.0001
1-yr- BMI –0.5612 (–1.1287, 0.0063) 0.0526
1-yr- PIGD Score 3.4132 (–0.0565, 6.8829) 0.0538
MDS-UPDRS Part III
Score On - Change
from Baseline
Clinical Site (US) 2.1511 (–0.1819, 4.4841) 0.0706
Gender (Male) 2.1375 (0.3268, 3.9482) 0.0208 0.0755
Baseline CSF amyloid-1–42 –0.2610 (–0.3659, –0.1562) <0.0001
N = 341 Baseline MDS-UPDRS Part III Score On –0.0025 (–0.0051, 0.0001) 0.0633
1-yr- MDS-UPDRS Part III Score On 0.5132 (0.4149, 0.6115) <0.0001
Mean putamen SBR - %
Change from Baseline
Baseline RBDSQ –0.8478 (–1.5740, –0.1216) 0.0223
1-yr- Mean putamen SBR 65.3565 (51.7328, 78.9803) <0.0001 0.3580
N = 313
Mean striatum SBR - %
Change from Baseline
Baseline Mean striatum SBR 7.2315 (2.2679, 12.1951) 0.0088
Baseline RBDSQ –0.6229 (–1.2910, 0.0452) 0.0645 0.4405
N = 302 1-yr- Mean striatum SBR 45.9181 (35.9935, 55.8427) <0.0001
1-yr- SCOPA-AUT –0.3251 (–0.6948, 0.0446) 0.0786
iAge, gender, disease duration, and the baseline value of the outcome were forced into each model.
of the MDS-UPDRS in the ON state, and its 1-yr-
(SP = 100.00%).
In all models that incorporated the STP variables,
the percentage of variance in the outcome accounted
for by the predictors in the model increased a few
percentages as compared to the model without STP,
though none exceeded 17.2%, and variance in the ON
state outcomes continued to be largely unexplained
by the models.
Multivariate models of short-term change
predictors of long-term change in DaTscan
binding measures
As shown in Table 4 (Supplementary Table 3),
1-yr- in mean putamen (SP = 100.00%) and base-
line RBDSQ score were predictors of long-term
(from 1-year to last follow-up) percent change in
mean putamen SBR from baseline. On the other hand,
baseline mean striatum SBR, baseline RBDSQ, 1-yr-
 in mean striatum SBR (SP = 100.00%), and 1-yr-
change in SCOPA-AUT (SP = 1.07%) predicted long-
term (2-year to last follow-up) percent change in
mean striatum SBR. In both models, CSF amyloid-
1–42 was no longer significantly associated with the
outcome. The predictors in the model accounted for
44.1% of the variance in percent change from baseline
in mean striatum SBR.
DISCUSSION
This analysis examined clinical, imaging and
biofluid predictors of progression in PD, assessed
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clinically with total and motor subscore of the MDS-
UPDRS and by imaging with DAT binding, to explore
whether baseline and short-term (1-year) change in
these measures can improve prediction of longer-
term change in PD. There are three key findings.
First, while a combination of baseline clinical, imag-
ing, and biofluid biomarker measures consistently
predicted change in MDS-UPDRS, the predictive
value in the models was low, accounting for <15%
of the variance in the outcome. Second, and in
contrast, this multimodal model did account for
a substantial percentage of the variance in DAT
binding change. Third, combining the short-term
change with baseline values of possible predictors
improved the percentage of the variance in the out-
come accounted for by the model especially for DAT
binding.
We found that a multimodal model consisting
of baseline clinical, CSF, and imaging measures
can predict motor progression. The clinical predic-
tors varied somewhat depending on the outcome
measure examined, which is not surprising con-
sidering that in treated patients, motor measures
are impacted by the effect of the underlying treat-
ment [9]. Generally, though, our results suggest
that motor progression is greater among men (sim-
ilar to other studies [2]). While clinical measures
of autonomic dysfunction (blood pressure measures
and/or questionnaire-based) were statistically asso-
ciated with greater motor disease progression, the
low percentage of selection of these variables in the
cross-validation indicates that these results should
be interpreted with caution. Lower baseline stri-
atal DAT binding was also a consistent predictor
of greater motor progression. Our findings add to
the accumulating evidence that DAT binding may
be a biomarker for PD disease progression [22–24].
It is of note that the Schwab and England did
not predict motor progression, in contrast to more
advanced cohorts [1]. Perhaps in earlier PD, DAT
measures are a more sensitive correlate of disabil-
ity, as compared to motor scores. Finally, lower
CSF amyloid-1–42 predicted motor progression,
though again here the low percentage of selection
in the cross-validation raises caution in interpreta-
tion of this result. Having said that, in prior studies,
CSF amyloid-1–42 has been associated with greater
-synuclein pathology in the cortex in advanced dis-
ease [25], suggesting a possible mechanism for this
association. It would be of interest to examine the
relationship between CSF amyloid-1–42 and sub-
cortical -synuclein pathology in earlier PD disease
stages, but our current data do not permit such an
analysis.
When DAT binding measures were examined as
the outcome, perhaps not surprisingly, baseline DAT
binding measures predicted the change in DAT bind-
ing, with a large effect size. Of interest is that higher
REM sleep behavior disorder (RBD) questionnaire
scores predicted greater decline in DAT binding, and
the cross-validation analysis adds strength to this
observed effect. This is consistent with the possibil-
ity that RBD is a marker of worse disease severity in
PD, likely due to more widespread neurodegeneration
[26, 27].
In general, adding the short-term changes in the
predictors, rather than using just the baseline val-
ues of those predictors, improved modeling of the
outcome, especially for DAT binding. The short-
term change of the outcome of interest was selected
>99% of the time in the cross-validation. These find-
ings are in line with the idea that, given the clinical
variability of PD, single baseline cross-sectional clin-
ical measures are likely not as useful as longitudinal
in predicting longer clinical trajectory. Our results
indicate that clinical and DAT binding trajectory
may be identifiable early on in the PD diagnosis,
and the trajectory exhibited early in disease may
reflect longer-term change. The utility of incorpo-
rating short-term changes as entry criteria into PD
clinical trials has not been examined. However, an
example from another neurodegenerative disease,
ALS, illustrates its potential utility. In a trial of the
agent edaravone as a modifier of disease progres-
sion in ALS, short-term change, over a 12-week
period, in a functional outcome score was used to
identify patients who progressed either too rapidly
or not at all. These patients were excluded from the
trial as it was felt that evaluation of the effect of
edaravone in these subgroups would not be useful
[28].
Several limitations of this study warrant mention.
The definition of “OFF” in PPMI, requiring hold-
ing of only levodopa or dopamine agonists for 6
hours, makes it challenging to extricate the effect
of PD medications on the results. In addition, while
overall retention in the PPMI cohort has been high,
there are some missing data longitudinally, and this
many influence the results. Furthermore, there is
some diagnostic accuracy in early PD, such that some
patients may have had alternate disorders marked by
parkinsonism and abnormal DAT imaging, includ-
ing the more severe neurodegenerative parkinsonian
syndromes. The number of cases with a revision of
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clinical diagnosis was low. However, additional unde-
tected misdiagnosed cases may have been included
in the sample. Future analyses using PPMI brain
bank data will help investigate this possibility in the
future.
The results of this analysis might be considered
in the context of an FDA regulatory guidance on
accelerated drug approval for serious conditions [29]
suggesting the concept of intermediate clinical out-
comes as measures that are “considered reasonably
likely to predict long-term benefit” (page 18). For
example, could baseline plus short-term changes in
MDS- UPDRS be considered a candidate intermedi-
ate clinical outcome in studies of diseases modifying
therapies with the caveat that long term benefit would
need to be proven? This approach therefore holds
the promise of improving the efficiency and possi-
bly shortening PD clinical trial duration. In terms
of the clinical applicability of our results, if future
work validates the predictors we have identified in
independent cohorts representative of the general PD
population, they may translate into clinical tools for
prognostication.
Our results show that baseline and short-term
change in measures of motor disability (MDS-
UPRRS) are the strongest predictors of longer-term
change in this clinically relevant metric and that base-
line and one-year change in striatal DAT binging are
predictors of longer-term change in this imaging mea-
sure. These findings if replicated, suggest baseline
combined with short-term change in PD predictors
may have value as proxies for longer-term change
in PD. These data may be considered in study design
strategies of PD clinical trials as tools to either gain an
early signal of a therapeutic intervention or to develop
an outcome for an adaptive design.
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